REGULATORY
JPWA Poll Finds Progress in Unit Price-Based Negotiations, but Frequent and Lengthy Bargaining Persists
One year after Japan’s health ministry revised its ethical drug distribution guidelines, a follow-up survey by the industry has found certain progress in unit price-based negotiations while highlighting persistent issues like frequent renegotiations and long-term contracts. The findings were presented…
To read the full story
Related Article
REGULATORY
- Japan Eyes Broader Healthcare Measures Addressing Sex-Based Health Issues
May 28, 2026
- MHLW Panel Deems 4 More “Drug Loss” Products as High-Need
May 27, 2026
- LDP Panel OKs Immunization Act Bill Aimed at Beyfortus NIP Use
May 27, 2026
- Japan Selects JN.1 Substrains for COVID Vaccines in 2026-2027 Season
May 27, 2026
- Ex-Minister Kato Preparing Parliamentary Group on Diabetes Issues
May 27, 2026
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…





